昂利康(002940):原料药与制剂一体化布局 驱动业绩稳定提升
昂利康(002940):Q3净利超预期 公司加速步入增长期
Anlikang (002940): the performance is in line with the expected growth of the two core varieties.
昂利康(002940):业绩低点已过 特色制剂和原料药驱动公司未来三年净利润年复合增速预计不低于35%
昂利康(002940)新股网下询价策略
昂利康(002940):新股网下申购询价建议报告(昂利康)
No Data
No Data